The best evidence available is that BPC-157 results in improved outcomes in muscle, tendon, ligament, and bone injury models in animals. There are probably trials ongoing, but if we are being honest about the totality of evidence available to us right now , it is irresponsible to claim either way that BPC-157 does or does not increase performance
The severity and type of rosacea varies by patient, as does the individuals triggers and response to certain treatments
It is ideal for researchers just starting out or those running short protocols at lower doses
Plan for 4 to 6 months
Controlling the role of BPC 157 likely involves its particular interaction with the major systems involved in wound healing, such as the NO-system (counteracted harmful events, arising from either NO-blockade or NOS-substrate application) (Sikiric et al., 2014) and the prostaglandins system (i.e., large extent of the counteracted NSAIDs toxicity (Sikiric et al., 2013) as well as counteracted developing and already formed adjuvant arthritis in rats (Sikiric et al., 1997c))
This means that it is a short string of amino acids designed to accomplish a task within the body